Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 63

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 63
---
 | Service-Based Vesting                                                                                                                                                                  | ​ |
| The performance period applicable to the PSUs will end on the change in control and the share price appreciation targets will be assessed using the per share value received by a holder of our ordinary shares in such change in control (the “CIC Value”). If the CIC Value is less than the closing price of an ordinary share on the date of grant of the PSUs of $10.35 per share (the “Base Value”), the PSUs will be forfeited in their entirety. At a CIC Value in between the Base Value and one of the share appreciation targets applicable to the award, achievement will be determined using straight-line interpolation. Any PSUs for which performance is not determined to be achieved as of the change in control will be forfeited. | ​ | ​ | Same service-based vesting as pre-change in control: four years from February 20, 2025, with 25% after one year and quarterly thereafter, subject to the officer’s continuous service. | ​ |

Corporate Governance Policies Share Ownership Guidelines Our named executive officers are subject to share ownership guidelines. The share ownership guidelines require each of our executive officers to own shares equal in value to a multiple of six times base salary for our CEO and two times base salary for our other executive officers. Ownership requirements may be satisfied with shares and RSUs, whether or not vested but excluding shares still subject to a performance condition. Executive officers are required to comply with these guidelines by January 1, 2023, or, if later, by the five-year anniversary of their becoming an executive officer. Thereafter, compliance is measured annually. If, at a compliance measurement date, a named executive officer does not meet the applicable guideline, then until such officer complies, he or she will be expected to hold 50% of our after-tax shares acquired thereafter, whether by option exercise, vesting or settlement of equity awards. All named executive officers are in compliance with our share ownership guidelines, with the exception of named executive officers who do not yet have sufficient tenure to require compliance with such guidelines. Clawback Policy Our named executive officers are subject to our clawback policy which, consistent with SEC and Nasdaq rules, requires the reimbursement of certain incentive-based compensation in the event of a restatement of our financial statements due to material noncompliance with any financial reporting requirement under U.S. securities laws. Equity Grant Policy Although we do not have a formal policy with respect to the timing of stock option grants, they are primarily used